ReviewThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2024
Harnessing the Power of AI for Enhanced Diagnosis and Treatment of Hepatocellular Carcinoma.
Review in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches.Cancers · 2026Review
- New understanding of the molecular pathogenesis and therapeutic progress of hepatocellular carcinoma.Oncology reviews · 2026Review
- Prediction of Histopathological Grade of Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Radiomics Features.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its advent, artificial intelligence (AI) has been continuously researched, and substantial progress has been made in many fields, such as the diagnosis and therapies for cancer. Due to the advantages of high efficiency, rapidity, and precision, AI has been increasingly adopted in the medical field to improve patient prognosis and the efficiency of medical procedures. Thus, AI technology has become a powerful driving force and support mechanism in the medical and health industry. Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer mortality worldwide, with a 5-year relative survival rate of 18%. The early diagnosis and postsurgical treatment of HCC are key factors related to its prognosis, which provides an opportunity for the application of AI in HCC diagnosis and treatment. This review will summarize the application of AI in the diagnosis and treatment of HCC to provide prospects for deeper and wider applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.